Oryzon Genomics SA
Barcelona
About Oryzon Genomics SA
Oryzon Genomics is a biopharmaceutical company developing epigenetics-based therapeutics for patients with cancer and CNS disorders. Oryzon is able to identify and validate biomarkers and therapeutic targets through its epigenetic platform and turn them into advanced and personalized therapies. Oryzon Genomics has a growing portfolio, with two compounds in Phase II clinical trials: iadademstat (aka ORY-1001), a potent and selective LSD1 inhibitor for oncology, and vafidemstat (aka ORY-2001), a CNS optimized LSD1 inhibitor for the treatment of neurological diseases. The portfolio includes ORY-3001, a selective LSD1 inhibitor in preclinical development for the treatment of non-oncological diseases.
Company Facts
- Operating status: Active
- Company type: For Profit
- IPO status: Public
- Employees: 11 – 50
- Estimated revenue: $10K – $50K
- Total funding: $262.1M
- Funding stage: IPO
- Last round: Grant (Jul 2025)
- Ticker: bme:ORY
- Website: oryzon.com
- Phone: 34 93 515 13 13
Industries & Categories
Biopharma, Biotechnology, Genetics, Health Care, Medical
Social Profiles
Canonical: https://fsome.com/organization/oryzon-genomics-sa-37596 · For the full interactive profile (charts, investors, team, acquisitions, press), please enable JavaScript.